Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 2.38
CYTR's Cash-to-Debt is ranked lower than
70% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. CYTR: 2.38 )
Ranked among companies with meaningful Cash-to-Debt only.
CYTR' s Cash-to-Debt Range Over the Past 10 Years
Min: 2.38  Med: No Debt Max: No Debt
Current: 2.38
Equity-to-Asset 0.40
CYTR's Equity-to-Asset is ranked lower than
75% of the 623 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. CYTR: 0.40 )
Ranked among companies with meaningful Equity-to-Asset only.
CYTR' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.16  Med: 0.74 Max: 0.89
Current: 0.4
0.16
0.89
Piotroski F-Score: 3
Altman Z-Score: -10.26
Beneish M-Score: -3.35
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -26128.50
CYTR's Operating Margin % is ranked lower than
96% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -92.73 vs. CYTR: -26128.50 )
Ranked among companies with meaningful Operating Margin % only.
CYTR' s Operating Margin % Range Over the Past 10 Years
Min: -63278  Med: -12974.5 Max: -80.47
Current: -26128.5
-63278
-80.47
Net Margin % -25385.00
CYTR's Net Margin % is ranked lower than
96% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -81.52 vs. CYTR: -25385.00 )
Ranked among companies with meaningful Net Margin % only.
CYTR' s Net Margin % Range Over the Past 10 Years
Min: -58587  Med: -10799.17 Max: 408
Current: -25385
-58587
408
ROE % -170.98
CYTR's ROE % is ranked lower than
88% of the 756 Companies
in the Global Biotechnology industry.

( Industry Median: -38.58 vs. CYTR: -170.98 )
Ranked among companies with meaningful ROE % only.
CYTR' s ROE % Range Over the Past 10 Years
Min: -232.62  Med: -86.58 Max: 1.39
Current: -170.98
-232.62
1.39
ROA % -77.07
CYTR's ROA % is ranked lower than
78% of the 855 Companies
in the Global Biotechnology industry.

( Industry Median: -33.01 vs. CYTR: -77.07 )
Ranked among companies with meaningful ROA % only.
CYTR' s ROA % Range Over the Past 10 Years
Min: -116.2  Med: -46.69 Max: 1.13
Current: -77.07
-116.2
1.13
ROC (Joel Greenblatt) % -2620.91
CYTR's ROC (Joel Greenblatt) % is ranked lower than
72% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: -496.85 vs. CYTR: -2620.91 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CYTR' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -12894.39  Med: -2849.72 Max: -723.27
Current: -2620.91
-12894.39
-723.27
3-Year Revenue Growth Rate -39.40
CYTR's 3-Year Revenue Growth Rate is ranked lower than
81% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. CYTR: -39.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CYTR' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -81.8  Med: -22.7 Max: 175.3
Current: -39.4
-81.8
175.3
3-Year EBITDA Growth Rate -11.10
CYTR's 3-Year EBITDA Growth Rate is ranked lower than
63% of the 506 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. CYTR: -11.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CYTR' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -67.2  Med: -11.1 Max: 143.5
Current: -11.1
-67.2
143.5
3-Year EPS without NRI Growth Rate -24.10
CYTR's 3-Year EPS without NRI Growth Rate is ranked lower than
74% of the 495 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. CYTR: -24.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CYTR' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -55.3  Med: -18.5 Max: 75.6
Current: -24.1
-55.3
75.6
GuruFocus has detected 3 Warning Signs with CytRx Corp $CYTR.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CYTR's 10-Y Financials

Financials (Next Earnings Date: 2017-06-10 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

CYTR Guru Trades in

CYTR Guru Trades in

Q3 2016

CYTR Guru Trades in Q3 2016

Jim Simons 690,380 sh (New)
» More
Q4 2016

CYTR Guru Trades in Q4 2016

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CYTR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:NVLS, NAS:MTP, AMEX:AMPE, NAS:CLBS, NAS:MIRN, OTCPK:BLEVF, OTCPK:IGXT, NAS:NVET, NAS:THLD, NAS:DMTX, NAS:EBIO, NAS:DMPI, NAS:PBMD, NAS:ITEK, OTCPK:COTQF, NAS:TRIL, OTCPK:CYYNF, OTCPK:PRTX, NAS:ARGS, OTCPK:DYAI » details
Traded in other countries:CX5N.Germany,
CytRx Corp is a biopharmaceutical research and development company specializing in oncology. Its oncology pipeline includes three clinical-stage drug candidates in various stages of development: Aldoxorubicin, Tamibarotene, and Bafetinib.

CytRx Corp is a Delaware corporation, incorporated in 1985. The Company is a biopharmaceutical research and development company specializing in oncology. Its oncology pipeline includes three clinical-stage drug candidates in various stages of development: Aldoxorubicin, Tamibarotene, and Bafetinib. Aldoxorubicin is a conjugate of the commonly prescribed chemotherapeutic agent doxorubicin that binds to circulating albumin in the bloodstream and is concentrated at the site of tumors. Tamibarotene is an orally available, synthetic retinoid, rationally designed to overcome resistance and reduce the toxic side effects of differentiation therapy with all-trans retinoic acid, a component of the current first-line treatment for acute promyelocytic leukemia, or APL. Bafetinib (formerly INNO-406) is an orally bioavailable, rationally-designed inhibitor of several Src kinases developed by the Japanese pharmaceutical company, Nippon Shinyaku, to overcome some of the limitations of Gleevec and other tyrosine kinase inhibitors in resistant chronic myelogenous leukemia. The Company do not have manufacture supplies of aldoxorubicin or any of our other product candidates accordingly it is dependent upon third-party manufactures, or potential future strategic alliance partners, to manufacture these supplies. The Company has manufacturing supply arrangements in place with respect to a portion of the clinical supplies needed for the clinical development programs for aldoxorubicin. The Company's plan is to establish its own sales force and marketing capability in order to commercialize aldoxorubicin in the U.S. and to seek a marketing partner for commercialization in other territories. It is subjected to a variety of federal, state and local regulations relating to the use, handling, storage and disposal of hazardous materials, including chemicals and radioactive and biological materials.

Ratios

vs
industry
vs
history
PB Ratio 2.05
CYTR's PB Ratio is ranked higher than
74% of the 975 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. CYTR: 2.05 )
Ranked among companies with meaningful PB Ratio only.
CYTR' s PB Ratio Range Over the Past 10 Years
Min: 1.39  Med: 3.59 Max: 67.04
Current: 2.05
1.39
67.04
PS Ratio 205.00
CYTR's PS Ratio is ranked lower than
88% of the 774 Companies
in the Global Biotechnology industry.

( Industry Median: 13.23 vs. CYTR: 205.00 )
Ranked among companies with meaningful PS Ratio only.
CYTR' s PS Ratio Range Over the Past 10 Years
Min: 3.49  Med: 210 Max: 2565
Current: 205
3.49
2565
EV-to-EBIT -0.37
CYTR's EV-to-EBIT is ranked lower than
99.99% of the 250 Companies
in the Global Biotechnology industry.

( Industry Median: 17.39 vs. CYTR: -0.37 )
Ranked among companies with meaningful EV-to-EBIT only.
CYTR' s EV-to-EBIT Range Over the Past 10 Years
Min: -17.5  Med: -2.8 Max: 0.2
Current: -0.37
-17.5
0.2
EV-to-EBITDA -0.37
CYTR's EV-to-EBITDA is ranked lower than
99.99% of the 274 Companies
in the Global Biotechnology industry.

( Industry Median: 15.67 vs. CYTR: -0.37 )
Ranked among companies with meaningful EV-to-EBITDA only.
CYTR' s EV-to-EBITDA Range Over the Past 10 Years
Min: -17.7  Med: -2.85 Max: 0.2
Current: -0.37
-17.7
0.2
Current Ratio 3.11
CYTR's Current Ratio is ranked lower than
61% of the 821 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. CYTR: 3.11 )
Ranked among companies with meaningful Current Ratio only.
CYTR' s Current Ratio Range Over the Past 10 Years
Min: 1.24  Med: 3.76 Max: 10.61
Current: 3.11
1.24
10.61
Quick Ratio 3.11
CYTR's Quick Ratio is ranked lower than
57% of the 820 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. CYTR: 3.11 )
Ranked among companies with meaningful Quick Ratio only.
CYTR' s Quick Ratio Range Over the Past 10 Years
Min: 1.24  Med: 3.76 Max: 10.61
Current: 3.11
1.24
10.61
Days Sales Outstanding 335.80
CYTR's Days Sales Outstanding is ranked lower than
95% of the 524 Companies
in the Global Biotechnology industry.

( Industry Median: 59.75 vs. CYTR: 335.80 )
Ranked among companies with meaningful Days Sales Outstanding only.
CYTR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 4.94  Med: 326.31 Max: 16870.3
Current: 335.8
4.94
16870.3

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -37.10
CYTR's 3-Year Average Share Buyback Ratio is ranked lower than
83% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. CYTR: -37.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CYTR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -53.9  Med: -29.5 Max: -7
Current: -37.1
-53.9
-7

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 2.42
CYTR's Price-to-Net-Cash is ranked higher than
82% of the 652 Companies
in the Global Biotechnology industry.

( Industry Median: 6.34 vs. CYTR: 2.42 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CYTR' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.55  Med: 4.93 Max: 108.26
Current: 2.42
0.55
108.26
Price-to-Net-Current-Asset-Value 2.28
CYTR's Price-to-Net-Current-Asset-Value is ranked higher than
83% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: 5.91 vs. CYTR: 2.28 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CYTR' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.54  Med: 4.27 Max: 108.89
Current: 2.28
0.54
108.89
Price-to-Tangible-Book 2.07
CYTR's Price-to-Tangible-Book is ranked higher than
78% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 4.44 vs. CYTR: 2.07 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CYTR' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.5  Med: 3.84 Max: 34.75
Current: 2.07
0.5
34.75
Price-to-Median-PS-Value 0.98
CYTR's Price-to-Median-PS-Value is ranked higher than
57% of the 673 Companies
in the Global Biotechnology industry.

( Industry Median: 1.02 vs. CYTR: 0.98 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CYTR' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.01  Med: 0.42 Max: 6.89
Current: 0.98
0.01
6.89
Earnings Yield (Greenblatt) % -270.27
CYTR's Earnings Yield (Greenblatt) % is ranked lower than
97% of the 1109 Companies
in the Global Biotechnology industry.

( Industry Median: -10.11 vs. CYTR: -270.27 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CYTR' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 572.4  Med: 1854.1 Max: 12962.6
Current: -270.27
572.4
12962.6

More Statistics

Revenue (TTM) (Mil) $0.20
EPS (TTM) $ -0.65
Beta1.50
Short Percentage of Float8.93%
52-Week Range $0.36 - 3.66
Shares Outstanding (Mil)117.32

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 11 28
EPS ($) -0.50 -0.41 -0.21
EPS without NRI ($) -0.50 -0.41 -0.21
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for CYTR

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: CYTR, API, CLGX, PLBC, ARTC Mar 05 2012 
Weekly CEO Buys Highlight: ULBI, BDE, ALNY, CTTR, GFN Feb 27 2012 
Weekly CFO Buys Highlight: CYTR, PZZI, AGYS, PLBC Feb 27 2012 
CytRx Corp. Reports Operating Results (10-K) Mar 11 2011 
CytRx Corp. Reports Operating Results (10-Q) Nov 08 2010 
CytRx Corp. Reports Operating Results (10-Q) Aug 09 2010 
CytRx Corp. Reports Operating Results (10-Q) May 06 2010 
CytRx Corp. Reports Operating Results (10-Q) Nov 09 2009 
CytRx Corp. Reports Operating Results (10-Q) Aug 07 2009 

More From Other Websites
CYTRX CORP Financials Mar 21 2017
CytRx Corp. :CYTR-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017 Mar 21 2017
CYTRX CORP Files SEC form 8-K, Results of Operations and Financial Condition Mar 15 2017
CytRx Reports 2016 Financial Results Mar 15 2017
[video]The 'Gnarly 9' Biotechs Will Test the FDA's Mettle Mar 08 2017
The 'Gnarly 9' Biotechs Will Test the FDA's Mettle Mar 08 2017
CytRx to Present at the 29th Annual ROTH Conference Mar 07 2017
CYTRX CORP Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or... Feb 24 2017
CytRx to Present at the 19th Annual BIO CEO & Investor Conference Feb 06 2017
CYTRX CORP Files SEC form 8-K, Change in Directors or Principal Officers Jan 13 2017
CYTRX CORP Files SEC form 8-K, Change in Directors or Principal Officers Jan 06 2017
CytRx Granted Type B Pre-NDA Meeting with U.S. FDA for Registration Pathway with Aldoxorubicin as a... Jan 04 2017
CytRx Granted Type B Pre-NDA Meeting with U.S. FDA for Registration Pathway with Aldoxorubicin as a... Jan 04 2017
Is the Options Market Predicting a Spike in CytRx Corp (CYTR) Stock? Dec 30 2016
CYTRX CORP Files SEC form 8-K, Change in Directors or Principal Officers Dec 19 2016
CytRx Appoints Chief Medical Officer Dr. Daniel Levitt as Chief Operating Officer Dec 19 2016
CytRx Appoints Chief Medical Officer Dr. Daniel Levitt as Chief Operating Officer Dec 19 2016
CYTRX CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Amendments to Articles of... Dec 14 2016
How CytRx Corporation (CYTR) Stacks Up Against Its Peers Dec 14 2016
CytRx Corporation Announces $8.1 Million Registered Direct Offering of Common Stock Dec 13 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)